Live webcast on what biosimilar companies need to know.
The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, announced today that it has scheduled a live webcast entitled: The BPCIA Patent Dance — What Biosimilar Companies Need To Know.
On or about seven years now, the Biologics Price Competition and Innovation Act (“BPCIA”) of 2009 has continually facilitated entry of biosimilar products into the market. By allowing submission of an abbreviated Biologics License Application (“aBLA”) to an already approved and licensed FDA product, BPCIA aids in making the pioneer and the applicant meet halfway. However, meeting halfway is not as easy as it sounds. There are matters to deal with: agreements and disclosures to be settled down before the commercial marketing of a biosimilar product begins. Patent disputes are among the most debated, and often controversial issues that biosimilar companies are faced with.
In its second part, BPCIA addresses certain patent resolution issues. Commonly called as the “patent dance”, 42 U.S.C. § 262(l) provides the steps and schedule when a reference sponsor product and a biosimilar applicant exchange “confidential information” about the aBLA. Typically, the confidential information disclosed by the applicant is its application and manufacturing trade secrets.
Indeed, the music hasn’t stopped for biosimilar companies, and “patent dance” is still obviously becoming a dance craze for them. Questions remain as to whether or not companies facing the “dance” will minimize the potential for litigation under the BPCIA, and to what extent will this craze bring the industry.
The Knowledge Group has assembled a panel of key thought leaders to provide the audience with an in-depth analysis of the BPCIA “Patent Dance” and its recent developments. In this two-hour LIVE Webcast, a panel of distinguished professionals and thought leaders will help biosimilar companies understand the important aspects of this significant topic. Speakers will also offer best practices in helping the audience better understand the steps and legal issues brought by the latest litigations.
Key Topics:
This 2-hour webcast will discuss the following key provisions:
-An Overview of 42 U.S.C. § 262(l)
-Nature of the abbreviated Biologics License Application (“aBLA”)
-The 180-day Notice of Commercial Marketing
-A Closer Look at the “Patent Dance”
-Deeper Study of the Significant Cases:
-Amgen v. Apotex
-Amgen v. Sandoz
Speakers/Faculty Panel
Pepper Hamilton LLP
Pierre E. Queiroz de Oliveira
Attorney
Nevrivy Patent Law Group P.L.L.C
Daniel J. Nevrivy, PH.D.
Attorney
Leydig, Voit & Mayer
Jamaica P. Szeliga
Partner
For an updated list of the faculty panel, please visit:
https://theknowledgegroup.org/event-homepage/?event_id=2114
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.